Accurate and rapid microfluidic ELISA to monitor Infliximab titers in patients with inflammatory bowel diseases

Iria, Inês; Soares, Ruben R. G.; Brás, Eduardo J. S.; Chu, V.; Gonçalves, João; Conde, J.P.

doi:10.1039/d1an01810h

Cited by 4 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, with BB_Trast and BB_Ipi, the recognition elements are specific to humanized IgG1 kappa monoclonal antibodies ( Goldenberg, 1999 ; Lipson and Drake, 2011 ), the antibody type most abundant in human sera ( Hamilton, 2014 ). TmAb titres have been successfully monitored using PoC platforms where 1:100 dilutions of patient samples were necessary ( Iria et al, 2022 ). Clinically relevant serum concentrations of trastuzumab are between 70 and 2000 nM and ipilimumab trough concentrations range between 30 and 230 nM ( Koguchi et al, 2020 ; Leyland-Jones et al, 2010 ).…”

Section: Discussionmentioning

confidence: 99%

Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies

Campbell

Adamson

Kohl

et al. 2023

Biosensors and Bioelectronics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies

Campbell

Adamson

Kohl

et al. 2023

Biosensors and Bioelectronics

View full text Add to dashboard Cite

A microfluidic platform for detection and quantification of two biomarkers for rheumatoid arthritis

Tsai

Kuo

et al. 2023

Sensors and Actuators B: Chemical

View full text Add to dashboard Cite

The use of vitamin D for patients with inflammatory bowel diseases

Matias

Lima

Nutels

et al. 2024

International Journal for Vitamin and Nutrition Research

View full text Add to dashboard Cite

Abstract. As Vitamin D (VD) plays an essential role in Inflammatory Bowel Diseases, this systematic review aimed to update the participation of this vitamin in the prevention or remission of these diseases. This review has included studies in MEDLINE–PubMed, EMBASE, and Cochrane databases. The authors have followed PRISMA (Preferred Reporting Items for a Systematic Review and Meta-analysis) guidelines. According to the inclusion and exclusion criteria, twenty-two randomized clinical trials were selected. In all, 1,209 patients were included in this systematic review: 1034 received only VD and 175 received VD in combination with calcium. The average doses of VD supplementation were from oral 400 IU daily to 10,000 IU per kilogram of body weight. Single injection of 300,000 IU of VD was also used. Several studies have shown the crucial role that VD plays in the therapeutic approach of IBD due to its effects on the immune system. It effectively decreased inflammatory cytokines such as TNF-α and IFN-γ (p<0.05) and provided a reduction in disease activity assessed through different scores such as Crohn’s Disease Activity Index (CDAI) (p<0.05) and Ulcerative Colitis Disease Activity Index (UCDAI) (p<0.05). Unfortunately, the available clinical trials do not have standardization of doses and routes of administration. Existing meta-analyses are biased because they compare studies using different doses or treatments in combination with different drugs or supplements such as calcium. Even though VD has crucial effects on inflammatory processes, there is still a need for standardized studies to establish how the supplementation should be performed and the doses to be administered.

show abstract

Accurate and rapid microfluidic ELISA to monitor Infliximab titers in patients with inflammatory bowel diseases

Abstract: Inflammatory bowel disease (IBD) is a term used to describe disorders that involve chronic inflammation in the gastrointestinal tract, affecting more than 6.8 million people worldwide.1 Biological therapy is used...

Cited by 4 publications

References 29 publications

Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies

Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies

A microfluidic platform for detection and quantification of two biomarkers for rheumatoid arthritis

The use of vitamin D for patients with inflammatory bowel diseases

Contact Info

Product

Resources

About